Experts in the field review integration of approved PARP inhibitors into advanced prostate cancer clinical practice.
Timothy J. Daskivich, MD
Advertisement
Articles by Timothy J. Daskivich, MD
Advertisement
Latest Updated Articles
Integrating PARP Inhibitors Into Advanced Prostate Cancer TherapeuticsPublished: March 17th 2021 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Regorafenib/Nivolumab Exhibits Nonsuperior Survival in Gastric Cancer
2
Pembrolizumab Combo Significantly Improves PFS/OS in Recurrent PROC
3
Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC
4
Tarlatamab Improves Survival Vs Chemotherapy in Second-Line SCLC Subgroups
5
